Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNC1
Period2020-01-01 → 2020-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100L1LQ.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥314m2020-01-01 → 2020-12-31StandaloneNet sales
Revenue¥1.3bn2019-01-01 → 2019-12-31StandaloneNet sales
Revenue¥169m2018-01-01 → 2018-12-31dStandaloneNet sales (5-year summary)
Revenue¥229m2017-01-01 → 2017-12-31dStandaloneNet sales (5-year summary)
Revenue¥178m2016-01-01 → 2016-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOperating income
Operating income−¥511m2019-01-01 → 2019-12-31StandaloneOperating income
Ordinary income−¥1.7bn2020-01-01 → 2020-12-31StandaloneOrdinary income
Ordinary income−¥539m2019-01-01 → 2019-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥864m2016-01-01 → 2016-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥2.1bn2020-01-01 → 2020-12-31StandaloneIncome before income taxes
Profit before tax−¥909m2019-01-01 → 2019-12-31StandaloneIncome before income taxes
Net income−¥2.1bn2020-01-01 → 2020-12-31StandaloneProfit loss
Net income−¥912m2019-01-01 → 2019-12-31StandaloneProfit loss
Net income−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet income loss (5-year summary)
Net income−¥931m2016-01-01 → 2016-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.8bnat 2020-12-31StandaloneAssets
Total assets¥4.4bnat 2019-12-31StandaloneAssets
Total assets¥3.4bnat 2018-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.5bnat 2017-12-31dStandaloneTotal assets (5-year summary)
Total assets¥3.1bnat 2016-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥793mat 2020-12-31StandaloneLiabilities
Total liabilities¥926mat 2019-12-31StandaloneLiabilities
Net assets / equity¥2.0bnat 2020-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2019-12-31StandaloneNet assets
Net assets / equity¥2.9bnat 2018-12-31dStandaloneNet assets
Net assets / equity¥2.9bnat 2017-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.6bnat 2016-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.1bnat 2020-12-31StandaloneCash and deposits
Cash and deposits¥3.3bnat 2019-12-31StandaloneCash and deposits
Cash & equivalents¥1.8bnat 2020-12-31StandaloneCash and cash equivalents
Cash & equivalents¥3.1bnat 2019-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2018-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.9bnat 2017-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥1.4bnat 2016-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥238m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥903m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥38m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥4m2019-01-01 → 2019-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥342m2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥257m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥242m2020-01-01 → 2020-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2019-01-01 → 2019-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.1bn2018-01-01 → 2018-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥6m2016-01-01 → 2016-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-145.582020-01-01 → 2020-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-65.552019-01-01 → 2019-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-104.552018-01-01 → 2018-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥136.43at 2020-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥240.71at 2019-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥216.61at 2018-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥263.54at 2017-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio71.4%at 2020-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2019-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.3%at 2018-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.9%at 2017-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued14,641,900at 2020-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued14,331,300at 2019-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,346,000at 2018-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,086,000at 2017-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees32at 2020-12-31StandaloneNumber of employees
Employees27at 2019-12-31StandaloneNumber of employees
Employees30at 2018-12-31dStandaloneNumber of employees
Employees29at 2017-12-31dStandaloneNumber of employees
Employees30at 2016-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 43
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2020-01-01 → 2020-12-31¥3m
Reconciling Itemsreconcilingdepreciation2020-01-01 → 2020-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2020-12-31¥2.7bn
Reconciling Itemsreconcilingsegment profit2020-01-01 → 2020-12-31−¥888m
Diagnostic Divisionreportable segmentcapex2020-01-01 → 2020-12-31¥14m
Diagnostic Divisionreportable segmentdepreciation2020-01-01 → 2020-12-31¥2m
Diagnostic Divisionreportable segmentemployeesat 2020-12-312 pure
Diagnostic Divisionreportable segmentrevenue2020-01-01 → 2020-12-31¥610,000
Diagnostic Divisionreportable segmentrevenue external2020-01-01 → 2020-12-31¥610,000
Diagnostic Divisionreportable segmentsegment assetsat 2020-12-31¥22m
Diagnostic Divisionreportable segmentsegment profit2020-01-01 → 2020-12-31−¥73m
Pharmaceutical Divisionreportable segmentemployeesat 2020-12-3112 pure
Pharmaceutical Divisionreportable segmentrevenue2020-01-01 → 2020-12-31¥314m
Pharmaceutical Divisionreportable segmentrevenue external2020-01-01 → 2020-12-31¥314m
Pharmaceutical Divisionreportable segmentsegment assetsat 2020-12-31¥91m
Pharmaceutical Divisionreportable segmentsegment profit2020-01-01 → 2020-12-31−¥713m
—segment totalemployeesat 2020-12-3114 pure
Total Of Reportable Segments And Otherssegment totalcapex2020-01-01 → 2020-12-31¥14m
Total Of Reportable Segments And Otherssegment totaldepreciation2020-01-01 → 2020-12-31¥2m
Total Of Reportable Segments And Otherssegment totalrevenue2020-01-01 → 2020-12-31¥314m
Total Of Reportable Segments And Otherssegment totalrevenue external2020-01-01 → 2020-12-31¥314m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2020-12-31¥113m
Total Of Reportable Segments And Otherssegment totalsegment profit2020-01-01 → 2020-12-31−¥787m
Reconciling Itemsreconcilingcapex2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingdepreciation2019-01-01 → 2019-12-31¥3m
Reconciling Itemsreconcilingsegment assetsat 2019-12-31¥3.9bn
Reconciling Itemsreconcilingsegment profit2019-01-01 → 2019-12-31−¥733m
Diagnostic Divisionreportable segmentcapex2019-01-01 → 2019-12-31¥10m
Diagnostic Divisionreportable segmentdepreciation2019-01-01 → 2019-12-31¥303,000
Diagnostic Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥11m
Diagnostic Divisionreportable segmentsegment assetsat 2019-12-31¥10m
Diagnostic Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31−¥152m
Pharmaceutical Divisionreportable segmentrevenue2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentrevenue external2019-01-01 → 2019-12-31¥1.3bn
Pharmaceutical Divisionreportable segmentsegment assetsat 2019-12-31¥420m
Pharmaceutical Divisionreportable segmentsegment profit2019-01-01 → 2019-12-31¥373m
Total Of Reportable Segments And Otherssegment totalcapex2019-01-01 → 2019-12-31¥10m
Total Of Reportable Segments And Otherssegment totaldepreciation2019-01-01 → 2019-12-31¥303,000
Total Of Reportable Segments And Otherssegment totalrevenue2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2019-01-01 → 2019-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2019-12-31¥430m
Total Of Reportable Segments And Otherssegment totalsegment profit2019-01-01 → 2019-12-31¥221m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 952
ItemContextValueUnit
Net cash provided by used in financing activities (5-year summary)Prior4YearDuration_NonConsolidatedMember6423000JPY
Net cash provided by used in financing activities (5-year summary)Prior3YearDuration_NonConsolidatedMember1476503000JPY
Net cash provided by used in financing activities (5-year summary)Prior2YearDuration_NonConsolidatedMember1147270000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration_NonConsolidatedMember1123312000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYearDuration_NonConsolidatedMember242261000JPY
Cash and cash equivalents (5-year summary)Prior4YearInstant_NonConsolidatedMember1418993000JPY
Cash and cash equivalents (5-year summary)Prior3YearInstant_NonConsolidatedMember1922454000JPY
Cash and cash equivalents (5-year summary)Prior2YearInstant_NonConsolidatedMember2218074000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant_NonConsolidatedMember3097514000JPY
Cash and cash equivalents (5-year summary)CurrentYearInstant_NonConsolidatedMember1822850000JPY
Number of employeesPrior4YearInstant_NonConsolidatedMember30
Number of employeesPrior3YearInstant_NonConsolidatedMember29
Number of employeesPrior2YearInstant_NonConsolidatedMember30
Number of employeesPrior1YearInstant_NonConsolidatedMember27
Number of employeesCurrentYearInstant_NonConsolidatedMember32
Average number of temporary workersPrior4YearInstant_NonConsolidatedMember6
Average number of temporary workersPrior3YearInstant_NonConsolidatedMember6
Average number of temporary workersPrior2YearInstant_NonConsolidatedMember6
Average number of temporary workersPrior1YearInstant_NonConsolidatedMember5
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember5
Total shareholder returnPrior4YearInstant_NonConsolidatedMember1.675
Total shareholder returnPrior3YearInstant_NonConsolidatedMember1.213
Total shareholder returnPrior2YearInstant_NonConsolidatedMember1.606
Total shareholder returnPrior1YearInstant_NonConsolidatedMember2.986
Total shareholder returnCurrentYearInstant_NonConsolidatedMember2.334
Total return on share price indexPrior4YearInstant_NonConsolidatedMember1.063
Total return on share price indexPrior3YearInstant_NonConsolidatedMember1.389
Total return on share price indexPrior2YearInstant_NonConsolidatedMember0.916
Total return on share price indexPrior1YearInstant_NonConsolidatedMember1.012
Total return on share price indexCurrentYearInstant_NonConsolidatedMember1.349
Number of employeesCurrentYearInstant_NonConsolidatedMember32
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember5
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember40.6
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember4.0
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember7819582JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember12
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember1
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember2
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember0
Number of employeesCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember14
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_ReportableSegmentsMember1
Number of employeesCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember18
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember_CorporateSharedMember4
Number of employeesCurrentYearInstant_NonConsolidatedMember32
Average number of temporary workersCurrentYearInstant_NonConsolidatedMember5
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E30058-000PharmaceuticalDivisionReportableSegmentsMember844805000JPY
Research and development expenses research and development activitiesCurrentYearDuration_jpcrp030000-asr_E30058-000DiagnosticDivisionReportableSegmentsMember57688000JPY
Research and development expenses research and development activitiesCurrentYearDuration987242000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration14381000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember14641900

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2019-12-31pass rounding
balance sheet identitynon_consolidated 2020-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2018-12-31pass
statement vs summary · net assetsnon_consolidated 2019-12-31pass
statement vs summary · net assetsnon_consolidated 2020-12-31pass
statement vs summary · operating cash flownon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · operating cash flownon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · revenuenon_consolidated 2019-01-01/2019-12-31pass
statement vs summary · revenuenon_consolidated 2020-01-01/2020-12-31pass
statement vs summary · total assetsnon_consolidated 2019-12-31pass
statement vs summary · total assetsnon_consolidated 2020-12-31pass